<p>The Childhood Asthma Management Program (CAMP) was designed to evaluate whether continuous, long-term treatment (over a period of four to six years) with either an inhaled corticosteroid (budesonide) or an inhaled noncorticosteroid drug (nedocromil) safely produces an improvement in lung growth as compared with treatment for symptoms only (with albuterol and, if necessary, prednisone, administered as needed). The primary outcome in the study was lung growth, as assessed by the change in forced expiratory volume in one second (FEV1, expressed as a percentage of the predicted value) after the administration of a bronchodilator. Secondary outcomes included the degree of airway responsiveness, morbidity, physical growth, and psychological development.</p>

NHLBI TOPMed: Childhood Asthma Management Program (CAMP)

Asthma study with Methylation (CpG), Metabolomics + 3 more data on BDC (2,785 participants)

NHLBI TOPMed: Childhood Asthma Management Program (CAMP)

Description

Applying For Access

Summary